News & Updates
Filter by Specialty:
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
16 Feb 2022
COVID-19 infection relatively rare in vaccinated IBD patients
Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.
COVID-19 infection relatively rare in vaccinated IBD patients
15 Feb 2022
Long-term PEN therapy promising in children with mild Crohn’s disease
Partial enteral nutritional (PEN) therapy shows potential in the long-term management of mild paediatric Crohn’s disease, helping to avoid the use of corticosteroids and prevent side effects commonly observed with other inflammatory bowel disease therapies, according to a study presented at the virtual Crohn's & Colitis Congress.
Long-term PEN therapy promising in children with mild Crohn’s disease
14 Feb 2022
Delaying endoscopies due to COVID-19 safe in IBD patients
Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).
